Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026
Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Fineline Cube May 9, 2026
Company Drug

Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance

Fineline Cube Jul 1, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...

Policy / Regulatory

China Unveils Measures to Boost Innovative Drug Development With Insurance Data Support

Fineline Cube Jul 1, 2025

China’s National Healthcare Security Administration (NHSA) and National Health Commission (NHC) jointly released the “Several...

Company Deals Drug

HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC

Fineline Cube Jul 1, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...

Company Deals

Recbio Partners with Biological E for HPV VaccineREC603’s India and Global Expansion

Fineline Cube Jul 1, 2025

China-based Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced a licensing agreement with India-headquartered Biological...

Company Drug

Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer

Fineline Cube Jul 1, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...

Others

Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices

Fineline Cube Jul 1, 2025

Departments including the Department of Industry and Information Technology, Health Commission, Healthcare Security Administration, and...

Company Drug

Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy

Fineline Cube Jul 1, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...

Company Deals

Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East

Fineline Cube Jul 1, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...

Company Drug

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Fineline Cube Jul 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...

Company Deals

Fosun Pharma Secures Licensing Deal for HCB101 SIRPα-Fc Fusion Protein

Fineline Cube Jul 1, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing...

Company Drug

Zai Lab’s Bemarituzumab Meets Phase III Endpoint in Gastric Cancer Trial

Fineline Cube Jul 1, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that its Phase III FORTITUDE-101...

Company Drug

Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...

Company Drug

Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC

Fineline Cube Jul 1, 2025

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...

Company Medical Device

MicroPort NeuroTech’s NUMEN Nest Gains FDA Marketing Approval

Fineline Cube Jul 1, 2025

China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of...

Company Drug

BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma

Fineline Cube Jul 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...

Company Deals

GenScript Receives $213.8M Payment from LaNova for PD-1 Antibody License

Fineline Cube Jun 30, 2025

China-based GenScript Biotech Corporation (HKG: 1548) announced that it has received a payment of USD...

Company Drug

UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder

Fineline Cube Jun 30, 2025

Belgium-based biopharma UCB (EBR: UCB) announced positive results from its Phase III GEMZ study, evaluating...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Company Deals

MGI Tech Partners with Italy’s Negedia to Advance Genomic Sequencing and Spatial Transcriptomics

Fineline Cube Jun 30, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. announced a collaboration with Italy’s Negedia to...

Posts pagination

1 … 131 132 133 … 662

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.